Imricor Expands Middle East Presence with Qatar Distribution Deal

Imricor Medical Systems, Inc. (ASX:IMR) has expanded its Middle East presence by signing a 5-year distribution agreement with East Agency WWL in Qatar. This collaboration grants East Agency exclusive rights to market and sell Imricor's iCMR cardiac ablation products in the country. Qatar becomes the second Middle Eastern nation, following Saudi Arabia, to offer Imricor's innovative ablation technology.

The CEO of East Agency, Mohamed Mekky, expressed enthusiasm, anticipating a transformative impact on ablation procedures in Qatar. Imricor's Chair and CEO, Steve Wedan, highlighted the strategic importance of this partnership, affirming the company's commitment to global expansion. The announcement marks a significant milestone for Imricor as it continues its growth trajectory in key markets, with plans for further expansion in the Middle East.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com